43.17

0.56% 0.24

Definium Therapeutics Inc (DFTX)

Overview News Price History Discussions Forecast

Definium Therapeutics Inc stock is traded at $43.17, with a volume of 1.12M. It is up +0.56% in the last 24 hours and up +2.47% over the past month. Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Previous Close:

$42.93

Open:

$43.9

24h Volume:

1.12M

Relative Volume:

0.41

Market Cap:

$5.73B

Revenue:

Net Income/Loss:

$-237.54M

P/E Ratio:

-17.25

EPS:

-2.5033

Net Cash Flow:

$-145.05M

1W Performance:

-2.53%

1M Performance:

+2.47%

6M Performance:

+148.10%

1Y Performance:

+0.00%

1-Day Range:

$42.69

$44.31

1-Week Range:

$41.57

$45.31

52-Week Range:

$14.62

$49.20

Definium Therapeutics Inc Stock (DFTX) Company Profile

Name

Definium Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

106

Twitter

Next Earnings Date

2026-07-30

Latest SEC Filings

DFTX's Discussions on Twitter

Compare DFTX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DFTX Definium Therapeutics Inc	43.17	5.73B	0	-237.54M	-145.05M	-2.5033
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Stifel	Buy
Apr-10-26	Initiated	Piper Sandler	Overweight
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-30-26	Initiated	Jefferies	Buy
Oct-13-25	Initiated	Needham	Buy
Aug-04-25	Resumed	Oppenheimer	Outperform
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Definium Therapeutics Inc Stock (DFTX) Latest News

Jul 24, 2026

DFTX Reiterated by Piper Sandler -- Price Target Raised to $73.0 - GuruFocus

Jul 24, 2026

Piper Sandler Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $73 - Moomoo

Jul 24, 2026

Piper Sandler raises Definium stock price target on DT120 outlook - Investing.com

Jul 24, 2026

DEFINIUM THERAPEUTICS INC : PIPER SANDLER RAISES TARGET PRICE TO $73 FROM $48 - Bitget

Jul 24, 2026

Jul 22, 2026

Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued? - Yahoo Finance

Jul 22, 2026

How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story - Yahoo Finance Singapore

Jul 22, 2026

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits

Jul 22, 2026

Jul 21, 2026